112 related articles for article (PubMed ID: 11863119)
1. Comparative effects of plasmapheresis and intravenous cyclophosphamide on urinary podocyte excretion in patients with proliferative Lupus nephritis.
Nakamura T; Ushiyama C; Hara M; Osada S; Ugai K; Shimada N; Hayashi K; Ebihara I; Koide H
Clin Nephrol; 2002 Feb; 57(2):108-13. PubMed ID: 11863119
[TBL] [Abstract][Full Text] [Related]
2. [The significance of urinary podocytes in patients with active lupus nephritis].
Li JZ; Liu Y; E J; Huang HC; Yu F; Zou WZ; Wang HY
Zhonghua Nei Ke Za Zhi; 2007 Feb; 46(2):127-30. PubMed ID: 17445439
[TBL] [Abstract][Full Text] [Related]
3. Urinary podocytes for the assessment of disease activity in lupus nephritis.
Nakamura T; Ushiyama C; Suzuki S; Hara M; Shimada N; Sekizuka K; Ebihara I; Koide H
Am J Med Sci; 2000 Aug; 320(2):112-6. PubMed ID: 10981486
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis.
Ong LM; Hooi LS; Lim TO; Goh BL; Ahmad G; Ghazalli R; Teo SM; Wong HS; Tan SY; Shaariah W; Tan CC; Morad Z
Nephrology (Carlton); 2005 Oct; 10(5):504-10. PubMed ID: 16221103
[TBL] [Abstract][Full Text] [Related]
5. Combination of immunoadsorption therapy and high-dose methylprednisolone in patients with lupus nephritis; possible indications in patients with early stage.
Funauchi M; Ikoma S; Imada A; Kanamaru A
J Clin Lab Immunol; 1997; 49(2):47-57. PubMed ID: 9819673
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic effect of double-filtration plasmapheresis combined with methylprednisolone to treat diffuse proliferative lupus nephritis.
Li M; Wang Y; Qiu Q; Wei R; Gao Y; Zhang L; Wang Y; Zhang X; Chen X
J Clin Apher; 2016 Aug; 31(4):375-80. PubMed ID: 26018932
[TBL] [Abstract][Full Text] [Related]
7. Outcome of low dose cyclophosphamide for induction phase treatment of lupus nephritis, a single center study.
Sigdel MR; Kafle MP; Shah DS
BMC Nephrol; 2016 Oct; 17(1):145. PubMed ID: 27717323
[TBL] [Abstract][Full Text] [Related]
8. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group.
Lewis EJ; Hunsicker LG; Lan SP; Rohde RD; Lachin JM
N Engl J Med; 1992 May; 326(21):1373-9. PubMed ID: 1569973
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].
Petrović R; Stojanović R; Novicić-Sasić D; Dimitrijević J; Pavlović S; Stojković D; Palić-Obradović D; Stevanović G; Prodanović S
Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():19-25. PubMed ID: 12583309
[TBL] [Abstract][Full Text] [Related]
10. Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis.
Danieli MG; Palmieri C; Salvi A; Refe MC; Strusi AS; Danieli G
J Clin Apher; 2002; 17(2):72-7. PubMed ID: 12210709
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of intravenous pulse cyclophosphamide in the treatment of severe lupus nephritis in children.
Tangnararatchakit K; Tapaneya-Olarn C; Tapaneya-Olarn W
J Med Assoc Thai; 1999 Nov; 82 Suppl 1():S104-10. PubMed ID: 10730528
[TBL] [Abstract][Full Text] [Related]
12. [Plasmapheresis in a case of necessary discontinuation of cyclophosphamide in the treatment of severe lupus nephritis].
Saracyn M; Korsak J; Wańkowicz Z
Pol Merkur Lekarski; 2004 Aug; 17(98):162-4. PubMed ID: 15603328
[TBL] [Abstract][Full Text] [Related]
13. Immunoadsorption plasmapheresis using a phenylalanine column as an effective treatment for lupus nephritis.
Sugimoto K; Yamaji K; Yang KS; Kanai Y; Tsuda H; Hashimoto H
Ther Apher Dial; 2006 Apr; 10(2):187-92. PubMed ID: 16684222
[TBL] [Abstract][Full Text] [Related]
14. Recurrent Proliferative Glomerulonephritis With Monoclonal IgG Deposits After a Renal Transplant Which Was Insensitive to Pulse Therapy Remitted by Double Filtration Plasmapheresis.
Wu D; Chen JS; Cheng DR; Chen H; Li X; Ji SM; Xie KN; Ni XF; Liu ZH; Wen JQ
Exp Clin Transplant; 2015 Oct; 13(5):467-70. PubMed ID: 25275829
[TBL] [Abstract][Full Text] [Related]
15. Induction therapy with short-term high-dose intravenous cyclophosphamide followed by mycophenolate mofetil in proliferative lupus nephritis.
Arends S; Berden JH; Grootscholten C; Derksen RH; Berger SP; de Sévaux RG; Voskuyl AE; Bijl M;
Neth J Med; 2014 Nov; 72(9):481-90. PubMed ID: 25431394
[TBL] [Abstract][Full Text] [Related]
16. Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group.
Pohl MA; Lan SP; Berl T
Ann Intern Med; 1991 Jun; 114(11):924-9. PubMed ID: 2024858
[TBL] [Abstract][Full Text] [Related]
17. [Plasmapheresis combined with pharmacology in the treatment of lupus nephritis: a new therapeutic protocol].
Russo GE; Bonello M; Vitaliano E; Bosco M; Maresca L; De Paola A; Tedaldi M; Bisciglia MF; Bauco B
Clin Ter; 2000; 151(1):9-13. PubMed ID: 10822875
[TBL] [Abstract][Full Text] [Related]
18. Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens.
Mok CC; Ho CT; Siu YP; Chan KW; Kwan TH; Lau CS; Wong RW; Au TC
Am J Kidney Dis; 2001 Aug; 38(2):256-64. PubMed ID: 11479150
[TBL] [Abstract][Full Text] [Related]
19. [Synchronizing therapy with plasmapheresis and cyclophosphamide in rapidly progressing systemic lupus erythematosis with kidney involvement].
Demin AA; Sentiakova TN; Smirnov VV; Demina LM; Mamin IV
Ter Arkh; 1996; 68(5):27-30. PubMed ID: 9082593
[TBL] [Abstract][Full Text] [Related]
20. Podocyte-associated mRNA profiles in kidney tissue and in urine of patients with active lupus nephritis.
dos Santos M; Bringhenti RN; Rodrigues PG; do Nascimento JF; Pereira SV; Zancan R; Monticielo OA; Gasparin AA; de Castro WP; Veronese FV
Int J Clin Exp Pathol; 2015; 8(5):4600-13. PubMed ID: 26191151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
